🟢 Biomea Fusion is trading 5% up today after completing Phase II trial enrollment

Biomea Fusion is trading 5.03% up at $1.67 after investors continued responding to the August 24 completion of enrollment in the COVALENT-211 Phase II icovamenib trial.

• The study enrolled 64 participants; primary endpoint data are expected in the first quarter of 2027.
• H.C. Wainwright reiterated a Buy rating and $4.00 price target, following the prior session’s 16.06% gain.
• Broader biotech strength added a tailwind, though the principal catalyst is company-specific.